Diagnosis of terminal hepatocellular carcinoma
Laminin gamma-2 monomer levels, measured via immunoassays, enhance liver cancer diagnosis and monitoring, addressing the limitations of current methods by providing sensitive and specific non-invasive staging of hepatocellular carcinoma.
JP2026516971APending Publication Date: 2026-05-27ABBOTT LAB INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ABBOTT LAB INC
- Filing Date
- 2024-04-26
- Publication Date
- 2026-05-27
AI Technical Summary
Technical Problem
Current diagnostic methods for liver cancer, particularly hepatocellular carcinoma, lack sensitivity and specificity for early detection and monitoring, and invasive procedures like liver biopsy pose risks and complications.
Method used
The use of laminin gamma-2 monomer (LG2m) concentration levels, determined through immunoassays with specific antibodies, to diagnose and monitor liver cancer progression, including hepatocellular carcinoma, by comparing LG2m levels to reference values.
Benefits of technology
Provides a non-invasive method for accurate staging and monitoring of liver cancer, reducing the need for invasive procedures and improving detection sensitivity and specificity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026516971000001_ABST
Abstract
Methods, systems, and kits for determining and monitoring the stage of liver cancer are provided herein. In particular, methods, systems, and kits are provided that use, optionally, a concentration, level, or amount of total LG2m, along with a concentration, level, or amount of full-length laminin gamma-2 monomer (LG2m), for determining or identifying the stage of liver cancer (e.g., hepatocellular carcinoma) in a subject.
Need to check novelty before this filing date? Find Prior Art